Journal: Frontiers in Chemistry

Article Title: Mechanism of hedysari radix praeparata cum melle and curcumae rhizoma herb pair in colitis-associated colorectal cancer through the MAPK/NF-κB signaling pathway: an investigation in vivo and in vitro

doi: 10.3389/fchem.2025.1551722

Figure Lengend Snippet: HRCR-MIAS intervention suppressed MAPK/NF-kB signaling pathway in SW620 cells. (A) Representative gel. Relative protein expressions of (B) NF-kB, (C) ERK/p-ERK, (D) MEKK1, (E) I-kB, and (F) RAS. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.0001 vs the AOM/DSS group.

Article Snippet: The primary antibodies including RAS antibody (21 kDa, 1:5000, ab52939, No. 1014133-14, Abcam, UK), ERK antibody (42, 44 kDa, 1:1000, ab201015, No. 1001375-16, ab184699, No. 1000861-11, Abcam, UK), p-ERK antibody (42, 44 kDa, 1:1000, No. #4695, No. 4370T, Cell Signaling Technology, America), MEKK1 antibody (195 kDa, 1:200, No. I1710, Santa Cruz Biotechnology, Inc., America), IkB antibody (36 kDa, 1:10000, ab32518, No. GR275907-51, Abcam, UK), NF-kB antibody (65 kDa, 1:10000, ab32536, No. GR3422076-12, Abcam, UK), GAPDH antibody (37 kDa, 1:10000, No. YM3092, Immunoway, America), and β-actin antibody (43 kDa, 1:3000, No. #AF7018, Affinity, China) were incubated followed by incubation of the secondary antibody, washed, and exposed with the gel imaging system.

Techniques:

Journal: Frontiers in Chemistry

Article Title: Mechanism of hedysari radix praeparata cum melle and curcumae rhizoma herb pair in colitis-associated colorectal cancer through the MAPK/NF-κB signaling pathway: an investigation in vivo and in vitro

doi: 10.3389/fchem.2025.1551722

Figure Lengend Snippet: HRCR intervention inhibited CAC mice’s MAPK/NF-kB signaling pathway. (A) Representative gel. Relative protein expression of (B) RAS, (C) ERK/p-ERK, (D) MEKK1, (E) IkB, and (F) NF-kB. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.0001 vs the AOM/DSS group.

Article Snippet: The primary antibodies including RAS antibody (21 kDa, 1:5000, ab52939, No. 1014133-14, Abcam, UK), ERK antibody (42, 44 kDa, 1:1000, ab201015, No. 1001375-16, ab184699, No. 1000861-11, Abcam, UK), p-ERK antibody (42, 44 kDa, 1:1000, No. #4695, No. 4370T, Cell Signaling Technology, America), MEKK1 antibody (195 kDa, 1:200, No. I1710, Santa Cruz Biotechnology, Inc., America), IkB antibody (36 kDa, 1:10000, ab32518, No. GR275907-51, Abcam, UK), NF-kB antibody (65 kDa, 1:10000, ab32536, No. GR3422076-12, Abcam, UK), GAPDH antibody (37 kDa, 1:10000, No. YM3092, Immunoway, America), and β-actin antibody (43 kDa, 1:3000, No. #AF7018, Affinity, China) were incubated followed by incubation of the secondary antibody, washed, and exposed with the gel imaging system.

Techniques: Expressing

Journal: PLoS ONE

Article Title: CCN2 Enhances Resistance to Cisplatin-Mediating Cell Apoptosis in Human Osteosarcoma

doi: 10.1371/journal.pone.0090159

Figure Lengend Snippet: (A) Protein expression was examined by western blotting. (B & C) Cells were transfected with FAK, MEK, and ERK mutants or pretreated with FAK inhibitor (10 µM), PD98059 (10 mM), and U0126 (10 µM), followed by stimulation with cisplatin for 24 h. Cell survival ability and apoptosis were examined by MTT assay and PI staining. Each experiment was done in triplicate. Results are expressed as mean ± SEM. *, p<0.05 as compared with MG-63/vector group; # P <0.05 compared with MG-63/CCN2 cisplatin-treated control group.

Article Snippet: The blots were blocked with 4% BSA for 1 h at room temperature and incubated with the following primary antibodies for 1 h at room temperature to detect antigen: mouse monoclonal anti-CCN2, Bcl-xL, survivin, or α-tubulin (Santa Cruz Biotechnology) or rabbit polyclonal anti-FAK, p-MEK, MEK, p-ERK, or ERK (Santa Cruz Biotechnology).

Techniques: Expressing, Western Blot, Transfection, MTT Assay, Staining, Plasmid Preparation